Adolescents
Psychedelic use among adolescents presents a complex interplay between cultural context, potential therapeutic benefits, and risks associated with mental health. Recent research suggests that while Western perspectives are largely negative, there is a growing interest in the potential for psychedelics to support mental health treatment in this demographic, particularly in therapeutic settings.
Key Insights
- 1
Cultural context plays a significant role in the perception and outcomes of psychedelic use among adolescents.
- 2
Preliminary studies suggest that ritualistic use of ayahuasca may lower the incidence of psychiatric symptoms compared to controls.
- 3
There is a budding recognition within the clinical community of psychedelics’ therapeutic potential for treating mental health disorders in adolescents.
- 4
MDMA has been shown to foster emotional support and may improve outcomes in psychotherapy for PTSD amidst young individuals.
- 5
Research suggests that psychedelics like psilocybin may be associated with lower rates of suicidal thoughts among adolescents.
What is Adolescents?
Adolescence, typically ranging from ages 10 to 19, is a critical period for brain development and mental health. The neuroplasticity of the adolescent brain may make it particularly vulnerable to the effects of psychoactive substances, including psychedelics. Common psychological issues during this stage include mood disorders, anxiety, and risk-taking behaviours, which can be exacerbated by substance use.
Adolescents may use psychedelics both recreationally and within cultural or therapeutic frameworks. Psychotropic substances like MDMA and ayahuasca are sometimes employed in ritualistic contexts within certain cultures, and evidence suggests that such contexts might mitigate risks.
Currently, there is a scarcity of rigorous studies examining the impact of psychedelic use on adolescent mental health, necessitating further exploration. The contrasting cultural reception of psychedelics indicates a need for a nuanced understanding of their effects across different societal settings.
Current Treatments
Standard treatments for mental health issues in adolescents primarily involve psychotherapy, medication (such as SSRIs), and lifestyle modifications. More recently, there is increasing interest in exploring the therapeutic potential of psychedelics, particularly for conditions like anxiety and PTSD among young patients.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Adolescents.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| MDMA There are emerging clinical findings supporting its utility in psychotherapy for adolescents, but robust clinical trials are still required. | Medium | Moderate | Inconsistent |
| Ayahuasca Initial studies suggest ayahuasca may lower psychiatric symptom risk in cultural contexts, but more controlled research is needed. | Medium | Moderate | Inconsistent |
| Psilocybin Evidence hints at its potential for improving mood disorders among adolescents, though further investigation is critically needed. | Medium | Moderate | Inconsistent |
| Ketamine Research shows promise for treatment-resistant depression in adolescents, yet methodological limitations persist. | Medium | Moderate | Inconsistent |
MDMA and Adolescents
MDMA, widely known as 'ecstasy', has been associated with increased empathy and emotional processing, making it a candidate for aiding psychotherapy in adolescents with PTSD. Initial investigations highlight that it may enhance therapeutic relationships and provide emotional release, yet concerns regarding misuse and long-term effects are evident in recreational contexts.
Ayahuasca and Adolescents
Ayahuasca, a psychoactive brew consumed culturally and spiritually among indigenous groups, has shown potential mental health benefits for adolescent users within ritualistic settings. Literature suggests that ayahuasca may provide insights into personal issues and assist in emotional healing, although its effects in uncontrolled recreational settings pose various mental health risks.
Psilocybin and Adolescents
Psilocybin, the active compound in magic mushrooms, has been explored for its efficacy in treating depression and anxiety among adolescents. Some studies suggest that it can lead to significant improvements in mood and a sense of connectedness, though rigorous clinical trials in this demographic are still in preliminary stages.
Ketamine and Adolescents
Ketamine has been noted for its rapid antidepressant effects, even among adolescents. While traditional antidepressants may take weeks to provide relief, ketamine shows promise in significantly alleviating depressive symptoms within hours in clinical settings. Its application remains under scrutiny, particularly regarding long-term safety and efficacy in younger populations.
Clinical Outlook
The future of psychedelic treatment for adolescents appears promising as clinical interest continues to grow in understanding the therapeutic potentials of these substances. Ongoing research may yield crucial insights into safely harnessing psychedelics for mental health treatment, potentially reshaping how we approach adolescent psychology and psychiatry.
Industrial Landscape
Key organisations involved in this research space include MAPS (Multidisciplinary Association for Psychedelic Studies) and numerous academic institutions exploring the intersections of psychedelics, mental health, and adolescence. Leading researchers like Rick Doblin advocate for the responsible exploration of psychedelics in therapeutic settings.
Quick Indicators
Organisations
Search →Janssen Research & Development
Janssen Research & Development is the pharmaceutical research and development arm of Johnson & Johnson (J&J). Operating under J&J's Innovative Medicine division, Janssen has sponsored clinical trials into ketamine-derived compounds, including esketamine (Spravato), the first FDA-approved psychedelic-adjacent treatment for treatment-resistant depression.
National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
Resilient Pharmaceuticals
Resilient Pharmaceuticals (formerly Lykos Therapeutics, formerly MAPS PBC) is a US-based public benefit corporation developing MDMA-assisted therapy for PTSD. It was founded in 2014 by MAPS (Multidisciplinary Association for Psychedelic Studies) as a commercial spinout to carry MAPS’ three decades of MDMA research through late-stage trials and regulatory approval. After completing two Phase 3 trials and filing an NDA in 2024, the FDA issued a Complete Response Letter (CRL) in August 2024, citing concerns about functional unblinding, durability of response, safety reporting at two trial sites, and the challenge of blinding psychedelic studies. The CRL requested a third Phase 3 trial. Following the rejection, the company laid off approximately 75% of staff. In May 2025, billionaire investors Antonio Gracias (Gracias Foundation) and Sir Christopher Hohn (TCI Fund) led a $50 million Series B recapitalisation, installing new leadership: CEO Mike Burke and CMO Javier Muniz. Rick Doblin, MAPS’ founder, remains supportive of the new direction. The company rebranded from Lykos Therapeutics to Resilient Pharmaceuticals on 28 August 2025, and continues to negotiate a path to FDA approval for MDMA-assisted therapy for PTSD.
MAPS
Nonprofit organizer and host of the Psychedelic Science conference series, alongside broader educational and policy programming.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
University of California, San Francisco
University of California, San Francisco (UCSF) hosts major psychedelic research activity through the Translational Psychedelic Research Program (TrPR), Neuroscape Psychedelics Division, and psychiatry-led clinical research on psychedelic-assisted therapies.
Imperial College London
The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
Columbia University
Research with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.
Massachusetts General Hospital
The Center for the Neuroscience of Psychedelics aims to better understand how psychedelics can be used to improve the treatment of mental illnesses. The core mission of the center is to understand exactly how psychedelics enhance the brain's capacity for change—or neuroplasticity—to optimize current treatments and render the term treatment resistant obsolete.
University of California San Diego
The Psychedelics and Health Research Initiative (PHRI) focuses heavily on conducting pilot studies and clinical trials while collecting diverse biometric data—including fMRI, EEG, and cognitive metrics—from study participants. This data-driven approach aims to unravel the biological and neurological underpinnings of how psychedelics facilitate healing.
Yale University
In 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
University of Wisconsin-Madison
The University of Wisconsin-Madison Transdisciplinary Center for Research in Psychoactive Substances is dedicated to exploring the scientific, historical, and cultural aspects of psychoactive substances, focusing on psychedelics.
People
Search →Hartej Gill
Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network
Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.
Jeanine Kamphuis
Psychiatrist and researcher at the Department for Mood Disorders, University Hospital Groningen (UMCG)
She studies ketamine, esketamine, and classic psychedelics for treatment-resistant psychiatric disorders, including depression, and is a coauthor on multiple psychedelic/ketamine reviews and clinical studies.
Joost Breeksema
Postdoctoral researcher and Executive Director of the OPEN Foundation
He is a prominent psychedelic researcher and advocate whose work helps shape evidence-based psychedelic policy, ethics, and patient-centered understanding of psychedelic and ketamine/esketamine treatments.
Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Jolien Veraart
Psychiatrist and PhD researcher at the University Medical Center Groningen / University of Groningen
She is a leading clinical researcher on ketamine and oral esketamine for treatment-resistant depression, including safety, efficacy, and real-world implementation.
Joshua Di Vincenzo
MSc researcher / clinical research staff member at the University Health Network and University of Toronto
He coauthors multiple systematic reviews and real-world studies on ketamine for treatment-resistant depression, making him a visible contributor to the evidence base on psychedelic-adjacent psychiatric therapeutics.
John Kelly
Associate Professor / Consultant General Psychiatrist at Trinity College Dublin
John R. Kelly is a leading academic psychiatrist in Ireland whose work has helped shape modern psychedelic psychiatry, including psilocybin research across depression, service-user attitudes, and transdiagnostic treatment frameworks.
Yvan Beaussant
Instructor in Medicine at Harvard Medical School and palliative care physician at Dana-Farber Cancer Institute
He is a leading clinical researcher in psychedelic-assisted therapy for serious illness, especially cancer-related depression, demoralization, and existential distress.
Kruti Joshi
Employee at Janssen Scientific Affairs, LLC
Joshi appears to be a Janssen-affiliated researcher coauthoring multiple real-world evidence studies on esketamine access, barriers, utilization, and economic outcomes in treatment-resistant depression.
Neşe Devenot
Senior Lecturer in the University Writing Program at Johns Hopkins University
Neşe Devenot is a notable critic and scholar of psychedelic medicine whose work examines ethics, public discourse, and the social meanings of psychedelic-assisted therapy.
David Mathai
Psychiatrist and Assistant Professor at The Johns Hopkins University School of Medicine
He is a psychiatric researcher at Johns Hopkins whose work spans psilocybin, ketamine/esketamine, and psychedelic-assisted psychotherapy, with multiple publications on experiential and therapeutic outcomes.
Heith Copes
Professor of Criminal Justice at the University of Alabama at Birmingham
Heith Copes is a criminologist whose research connects drug use, identity, and narrative meaning, including multiple collaborations on classic psychedelics, microdosing, and related social/behavioral outcomes.
Connected Evidence
The latest clinical data and verified academic findings associated with Adolescents.